Product Description
AGR2 Antibody | 7247 | ProSci
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: Rabbit polyclonal AGR2 antibody was raised against a 17 amino acid peptide near the amino terminus of human AGR2.
The immunogen is located within the first 50 amino acids of AGR2.
Research Area: Cancer, Cell Cycle
Tested Application: E, WB, IHC-P, IF
Application: AGR2 antibody can be used for detection of AGR2 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Specificiy: Two isoforms of AGR2 exists as a result of alternative splicing event.
Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate
Positive Control 2: Cat. No. 11-801 - Human Small Intestine Tissue Slide
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 19 kDa
Validation: N/A
Isoform: N/A
Purification: AGR2 Antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: AGR2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: AGR2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: AGR2 Antibody: AG2, GOB-4, HAG-2, XAG-2, PDIA17, HEL-S-116, AG2, UNQ515/PRO1030, Anterior gradient protein 2 homolog, HPC8, AG-2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: AGR2 Antibody: AGR2 (anterior gradient protein 2) and AGR3 are members of the anterior gradient homolog family. They are secreted cytoplasmic proteins which are involved in metastasis induction and p53 tumour supressor inhibition. They may serve as molecular markers and potential therapeutic targets for hormone-responsive breast tumours. AGR2 is ubiquitously expressed with upregulated expression in prostate cancer, breast cancer, lung cancer, renal carcinomas and endometrial carcinomas. AGR2 expression is positively correlated with that of the estrogen receptor (ER) and is negatively correlated with that of the epidermal growth factor receptor (EGFR) .